Amarin Corporation (AMRN)
The price, the headline numbers and the latest news, in one place.
Amarin Corporation (AMRN) Stock Price, Analysis & Data
| Bid | 12.16 |
| Market Cap | 300.47M |
| Revenue (ttm) | 186.23M |
| Net Income (ttm) | -27.12M |
| 0.77 | |
| -1.2 | |
| n/a | |
| 14.52 | |
| P/B (ttm) | 0.67 |
| P/S (ttm) | 1.60 |
| Earnings Date | Apr 29, 2021 |
| Ask | 14.11 |
| Volume | 31,497 |
| Avg. Volume (20D) | 74,419 |
| Open | 14.22 |
| Previous Close | 14.38 |
| Day's Range | 14.05 - 14.36 |
| 52-Week Range | 12.96 - 20.90 |
| Analyst | n/a |
| Price Target | 12 (-14.65%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesale...
Financial Performance
In 2025, Amarin's revenue was 213.65M, a decrease of -6.55% compared to the previous year's 228.61M. Earnings were -38.8M, a decrease of -52.79%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for AMRN stock is "null". The 12-month stock price forecast is 12, which is downside of 14.65% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
